MYCOLab Ai Logo - gold and army green

Impact of a Limosilactobacillus fermentum, Quercetin, and Resveratrol Nutraceutical on Fecal Microbiota Composition and Metabolic Activity in Healthy and Hypertensive Subjects

Summary

Researchers tested a dietary supplement containing beneficial bacteria and plant compounds on human gut microbiota samples. The supplement successfully modified the composition and activity of gut bacteria in both healthy and high blood pressure patients. The supplement increased production of beneficial acids and modified which bacteria were present in the fermentation samples. These findings suggest this type of supplement could potentially help manage high blood pressure by improving gut health.

Background

Arterial hypertension is associated with gut dysbiosis, and evidence suggests a bidirectional relationship between hypertension and alterations in intestinal microbiota composition. Modulation of the gut microbiota through prebiotics, probiotics, and bioactive compounds represents a promising therapeutic strategy for managing hypertension.

Objective

This study evaluated the effects of a nutraceutical product composed of three strains of Limosilactobacillus fermentum, quercetin, and resveratrol on the intestinal microbiome composition and metabolic activity of fecal samples from healthy and hypertensive subjects during in vitro fermentation.

Results

The nutraceutical modulated β-diversity similarly between healthy and hypertensive groups after fermentation. It increased relative abundance of Enterobacteriaceae in healthy controls and Lachnospiraceae in hypertensive subjects. The LfQR formulation significantly elevated levels of maltose, fructose, glucose, lactic acid, acetic acid, and succinic acid compared to control media.

Conclusion

The nutraceutical formulation effectively modulated intestinal microbiota composition and microbial metabolic activity in both healthy and hypertensive subjects during in vitro fermentation. Although results showed heterogeneous effects between groups, the formulation demonstrated potential for modulating the gut microbiome as an adjuvant therapeutic strategy for hypertension management.
  • Published in:Foods,
  • Study Type:In vitro Fermentation Study,
  • Source: PMID: 40231971, DOI: 10.3390/foods14060986
Scroll to Top